The Tocharian subjunctive Peyrot, M.
3
0
0
Hele tekst
(2) . ;,E9>77HI;IK8@KD9J?;< ? NQ?? 0I=B;;LM? N;F?H ?H TCDH <?E?H> OCN >I=OG?HN?H >C? A?PIH>?H TCDH CH B?NHIIL>Q?MN?HP;H BCH; CH>?BOC>CA?;ONIHIG?+?CAI?LM?L?ACI4HDCHA+?C oCH·; C?>I=OG?HN?H<?MN;;HPIILH;G?FCDEOCN<I?>>BCMNCM=B?B;H>M=BLC@N?H?H >;N?L?H IHA?P??L P;H B?N D;;L NIN B?N D;;L P;H IHT? D;;LN?FFCHA $?N 0I=B;;LMMN;GN;@P;HB?N,LINI %H>I !OLIJ??MB?NCMP?LQ;HN;;HIH>?LG??LB?N *?>?LF;H>M B?N !HA?FM B?N (;NCDH ?H B?N #LC?EM H>?LM >;H CH ;H>?L? %H>I. !OLIJ?M? N;F?H QIL>N B?N 0I=B;;LM? Q?LEQIIL> A?E?HG?LEN >IIL ??H <;M;F? IH>?LM=B?C>CHA NOMM?H ??H JL?M?HM ?H ??H MO<DOH=NC?@ $?N JL?M?HM E;H P?LA?F?E?H QIL>?H G?N B?N *?>?LF;H>M? JL?M?HM G;;L P;H >? MO<DOH=NC?@ <?MN;;N A??H >OC>?FCDE?N?A?HB;HA?LCHBII@>TCHH?HCM>?<;MCM<?N?E?HCMNI?EIG?H>?NCD> N?LQCDF BCDCH<CDTCHH?HP?LM=BCFF?H>?@OH=NC?MB??@N Q;;LIH>?LPIILQ;;L>? >I?F B?LB;FCHA ?HIH<?J;;F>B?C> ;HA?TC?HB?NJL?M?HMT?E?L<;M;F?LCM>;H>?MO<DOH=NC?@Q;N<?NL?@N>?@OH=NC? CM B?N P?LQIH>?LFCDE >;N B?N JL?M?HM IP?L B?N ;FA?G??H ;@A?F?C> FCDEN N? TCDH P;H >? MO<DOH=NC?@ G?N??H ?RNL; MO@@CR H>?LMTCHM FCDEN >?MO<DOH=NC?@ P;;E TIT??L IJ B?N JL?M?HM >;N B?N P?LM=BCF MIGM ;FF??H TC=BN<;;L CM ;FM P;H ??H Q?LEQIIL> <?C>? @ILG;NC?M <?E?H> TCDH >? EILN?L? CM >;H G??MN;F >? MO<DOH=NC?@ ?H >? F;HA?L? B?N JL?M?HM N?LQCDF >? OCNA;HA?H >?T?F@>? TCDH @A?TC?H P;H >? OCNA;HA?H FCDEN >? MO<DOH=NC?@DOCMNG??LIJB?NJL?N?LCNOG >?P?LF?>?HNCD> ?<?F;HALCDEMN?PILGP?L. M=BCFF?HNOMM?H>?MO<DOH=NC?@?HB?NJL?N?LCNOG<?NL?@@?H>?@F?RC? 6ITCDH>?J;F;N;. FCM?LCHAM ?H;<F;ONJ;NLIH?HHC?NB?F?G;;FB?NT?F@>? ?HB??@NCH0I=B;;LM >?MO<. DOH=NC?@P;;E<?ACH;==?HNN?A?HIP?LMO@@CR;==?HNCHB?NJL?N?LCNOG %H B?N >?<;N IP?L >? IILMJLIHA P;H >? 0I=B;;LM? MO<DOH=NC?@ B??@N B?N ,LINI. %H>I !OLIJ?M? J?L@?=NOG ??H ALIN? LIF A?MJ??F> /IGGCA? MO<DOH=NC?@MN;GG?H B?<<?HH;G?FCDE??H;<F;ON>C?E;HQIL>?HN?LOAA?PI?L>IJ;ª Q;NCH??LMN?CH. MN;HNC? OCN E f FCDEN N? EIG?H ?R;=N B?N ;<F;ONJ;NLIIH P;H B?N ,LINI %H>I. !OLIJ?M?J?L@?=NOG $?NALIINMN?<?TQ;;LN?A?H>?T?NB?ILC?CM>;NT?HC?NPIILMJ?FN CH M;BA; MO<DOH=NC?@MN;GG?H >CN MJ?=C@C?E? ;<F;ONJ;NLIIH IJNL??>N ?H >;N T? A??H MI?F;;M<C?>NPIIL>?<?N?E?HCM !?H<?N?L?P?LEF;LCHA<C?>N>?,LINI %H>I !OLIJ?M?I ;ILCMN Q;;LP;H>?; ;<F;ONIIE;ªTIOQIL>?HCHB?N0I=B;;LM !?HJLI<F??G>;;L<CDCM>;NTIQ?F;FM ; ??H PIIL;@A;;H>? =IHMIH;HN TIO B?<<?H GI?N?H J;F;N;FCM?L?H N?LQCDF >;N CH >? 0I=B;;LM?MO<DOH=NC?@DOCMNHC?NB?NA?P;FCM 3;;LM=BCDHFCDEQ?L>CH??LMN?CHMN;HNC? >? J;F;N;FCM?LCHAP;Hª OCN ,LINI %H>I !OLIJ??M ;Q?AA?Q?LEN H;;L ;H;FIAC? P;H B?NPIILB?N0I=B;;LMTIE;L;EN?LCMNC?E?I JL?M?HM >;NP;;EA?EIJJ?F>CM;;H>?;<. F;ON?H>? MO<DOH=NC?@ ?H MSH=BLIIHª NL;J B??@N TIH>?L PIIL;@A;;H>? J;F;N;FCM?LCHA .
(3) . I7C;DL7JJ?D=?D>;J&;:;HB7D:I. 2?LPIFA?HMGI?NIJ<;MCMP;H>?T?HC?N A?J;F;N;FCM??L>?ª NL;J>?J;F;N;FCM?LCHAP;H >? 0I=B;;LM? ; NL;J OCN ,LINI %H>I !OLIJ??M TCDH Q?AA?Q?LEN !?H ;H>?L JLI<F??GCM>;N>?MO<DOH=NC?@HIICN??HI ?F?G?HNB??@N G;;L>?IP;H>?I ;ILCMN TIO T?E?L CH ??H ;;HN;F PILG?H P;H B?N J;L;>CAG; EF;HEQ?NNCA TCDH Q?AA?P;FF?H Q;;LH;>? I P;H >?IP?LCA? PILG?H ;H;FIIA E;H TCDHP?LQCD>?L> $?NPIIL>??F P;H >?T? P?LEF;LCHA CM >;N B?N >? MNLC=N? EIJJ?FCHA P;H ??H P;H >? NQ?? ;<F;ON?H>? MO<DOH=NC?@NSJ?M ;;H B?N I JL?N?LCNOG P?LEF;;LN TIQ?F >;N MO<DOH=NC?@NSJ? ;FM B?N 0I=B;;LM?I JL?N?LCNOGA;;HN?LOAIJ>?,LINI %H>I !OLIJ?M?I ;ILCMN G;;L>?ICM P?L>Q?H?HOCN>?MO<DOH=NC?@ 2;HOCN>CNI ;ILCMNNSJ?GI?N>?MJ?=C@C?E?MO<DOH=NC?@. ;<F;ONTCDHOCNA?<L?C>H;;LB?N;H>?L?;<F;ON?H>?MO<DOH=NC?@NSJ? ?IHNQCEE?FCHAP;H>?<?N?E?HCMP;H>?0I=B;;LM?MO<DOH=NC?@CMQ;;LM=BCDHFCDE N? <?ALCDJ?H ;FM ??H NQ??>? JL?M?HM P;H >? J?L@?=NC?P? JL?N?LCNOGMN;G >;N P;HT?F@ ??H @ONOLOG<?N?E?HCM EL??A ? ;@F?C>CHA P;H >? MO<DOH=NC?@ OCN >? ;ILCMN P?LEF;;LN >;;LH;;MN ??H MJ?=C;F? ALI?J P;H Q?LEQIIL>?H >C? A??H MO<DOH=NC?@ B?<<?H G;;L Q;;LB?NJL?M?HMIIE;FMMO<DOH=NC?@A?<LOCENQIL>N ?JL?M?HM MO<DOH=NC?@P;H>C? Q?LEQIIL>?H A;;N N?LOA IJ ??H IO> JL?M?HM ~@ T? B?<<?H >? ;ILCMN IG OCN??H. FIJ?H>? L?>?H?H P?LFIL?H ~@ T? B?<<?H HIICN ??H ;ILCMN A?B;> CH B?N ,LINI %H>I. !OLIJ??M .
(4)
GERELATEERDE DOCUMENTEN
Since expression of Serpins may facilitate the immune escape of HLA positive tumors, we next analysed the effect of Serpin expression on survival in cases with normal/partial
Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden.. Note: To cite this publication please use the final
Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden.. Note: To cite this publication please use the final
Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden.. Note: To cite this publication please use the final
Detection of amyloid plaques in mouse models of Alzheimer’s disease by magnetic resonance imaging.. Apostolova
Peripheral blood cells were stained with HLA-A2.1 tetramers containing the tyrosinase368–376 peptide followed by staining with a panel of lineage antibodies, as described in
Blades and blade fragments seem to have been especially used for longitudinal motions, mainly on plant material (7/12). Flake and flake fragments are used in different motions on
This shape also occurs in the combination artefacts (see below). The shape is the result of intensive use in a repetitive abrasive motion, carried out from different angles. In
